News & Updates

The novel neoadjuvant therapy S-1, an oral fluoropyrimidine agent containing tegafur, gimeracil, and oteracil potassium, yields promising survival outcomes in high-risk patients with resectable pancreatic ductal adenocarcinoma, a recent study has found.

Permanent prostate brachytherapy can be delivered safely and effectively by adhering to established standards, suggests a recent study.

A compact device that incorporates high-resolution millimetre-wave imaging (HR-MMWI) can diagnose malignant skin lesions as accurately as clinical examination and other detection techniques, potentially cutting the number of unnecessary biopsies in half, as reported in a study.

Treatment with endoscopic submucosal dissection (ESD) for rectal tumours extending to the dentate line (RTDLs) remains safe and feasible despite its poorer outcomes relative to non-RTDLs if appropriate lesions are handled by experienced operators, suggests a study.

In what has been dubbed as ‘a small but mighty study’ at ASCO 2022, a phase II trial spearheaded by investigators from Memorial Sloan Kettering Cancer Center in New York, US heralded the remarkable efficacy and safety of the monoclonal antibody dostarlimab for the treatment of locally advanced mismatch repair-deficient (dMMR) rectal cancer.